申请人:SALZMAN GROUP LTD.
公开号:US20220324809A1
公开(公告)日:2022-10-13
Compounds and compositions including an ATP-regulated potassium (K
ATP
) channel opener can be including in pharmaceutical compositions. These compounds and compositions are useful for prevention, treatment, or management of pulmonary arterial or venous hypertension. The composition including the compounds may be formulated for intravenous, intraarterial, intramuscular, intranasal, rectal, anal, intravaginal, intratracheal, intraperitoneal, or subcutaneous, administration, or for inhalation.